The advent of nanotechnology holds the promise of new modalities for the treatment of disease inman. In particular, the multifunctional nature of nanoplatforms is well-suited for complex diseases thatinvolve several different cellular compartments, such as cancer. The overall objective of project 6 is todevelop and test programmable, or 'smart' nanoplatforms (SNaPs) that are based on common nanoplatformcores. Nanoplatforms have been designed which will undergo spontaneous self-assembly, based on hostguestchemical interactions. The assembly is dependent upon integration of polyethyleneglycol polymer(PEG)-conjugated molecular guests, where the distal terminus of the PEG polymer can be conjugated to'programmable' elements. This host-guest based nanoplatform provides several advantages over ourexisting platforms: the poor pharmacological properties associated with many potent drugs are actuallyexploited in this approach, with fewer expected side effects, the design is highly flexible, accommodatingmultiple therapeutic, imaging, targeting or other effector functions within each nanoplatform, and thenanoplatforms are easily and rapidly programmable by-simple coincubation of the host and guest moieties.The capacity to incorporate multiple targeting elements into the SNaPs will be used to evaluate whether lowaffinity/high avidity modes of targeting represent an improvement in target cognition over current highaffinity/low avidity approaches. We hypothesize that moderate-to-low affinity, high-avidity dependentinteractions offer increased opportunities for true 'recognition' of the platform target, particularly ifheterogenous recognition of several different 'sensor-ligands' is required. Finally, we will test the capacity ofthe programmable nanoplatform to target distinct cell populations that contribute to tumor growth andmalignancy, including both vascular and tumor elements, using syngeneic and transgenic models of disease.A focus of these investigations will be the efficacy of the nanoplatform, when used to eradicate residual andmetastatic disease, after ablation of the primary tumor. The capacity for SNaPs to hunt and kill residualdisease is a potential strength of the nanoplatform, as recurring and metastatic disease accounts for themajority of disease morbidity. These studies will lay the groundwork for a new generation of easilyprogrammed, multifunctional nanoplatforms, amenable to the treatment of malignancy in human patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA119335-01
Application #
7067860
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Project Start
2005-09-01
Project End
2010-08-31
Budget Start
2005-09-30
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$129,680
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Schutt, Carolyn; Ibsen, Stuart; Zahavy, Eran et al. (2017) Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin. Pharm Res 34:2025-2035
Heineck, D P; Lewis, J M; Heller, M J (2017) Electrokinetic device design and constraints for use in high conductance solutions. Electrophoresis 38:1475-1482
Manouchehri, Sareh; Ibsen, Stuart; Wright, Jennifer et al. (2016) Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol 5:27-35
Sandoval, Sergio; Mendez, Natalie; Alfaro, Jesus G et al. (2015) Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform. J Biomed Opt 20:88003
Goodwin, Andrew P; Nakatsuka, Matthew A; Mattrey, Robert F (2015) Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:111-23
Campbell, Diahnn F; Saenz, Rebecca; Bharati, Ila S et al. (2015) Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. Breast Cancer Res 17:48
Ortac, Inanc; Simberg, Dmitri; Yeh, Ya-san et al. (2014) Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Lett 14:3023-32
Sonnenberg, Avery; Marciniak, Jennifer Y; Rassenti, Laura et al. (2014) Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem 60:500-9
Saenz, R; Messmer, B; Futalan, D et al. (2014) Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. Mol Immunol 57:191-9
Sonnenberg, Avery; Marciniak, Jennifer Y; Skowronski, Elaine A et al. (2014) Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis 35:1828-36

Showing the most recent 10 out of 146 publications